In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

@inproceedings{Ahmed2013InSD,
  title={In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors},
  author={M Ahmed and Yehuda Goldgur and Jian Hu and Hong-fen Guo and Nai-Kong V Cheung},
  booktitle={PloS one},
  year={2013}
}
Ganglioside GD2 is a cell surface glycolipid that is highly expressed on cancer cells of neuroectodermal origin, including neuroblastoma, retinoblastoma, melanoma, sarcomas, brain tumors and small cell lung cancer. Monoclonal antibodies (MoAb) that target GD2 have shown clinical efficacy in the treatment of GD2 expressing tumors, and are expected to be the new standard of care for the treatment of pediatric neuroblastoma. In this study, the crystal structure of anti-GD2 murine MoAb 3F8 was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Anti-GD2 immunotherapy for neuroblastoma.

Expert review of anticancer therapy • 2017
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Design of therapeutic proteins with enhanced stability.

Proceedings of the National Academy of Sciences of the United States of America • 2009
View 2 Excerpts

Similar Papers

Loading similar papers…